XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.20.2

Stock-Based Compensation | 12 Months Ended
--- | ---
Jun. 30, 2020
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | Stock-Based Compensation Our shareholders previously approved the Lancaster Colony Corporation 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan reserved 1,500,000 common shares for issuance to our employees and directors. All awards granted under this plan will be exercisable at prices not less than fair market value as of the date of the grant. The vesting period for awards granted under this plan varies as to the type of award granted, and the maximum term of these awards is seven years. We recognize compensation expense over the requisite service period of the grant. Compensation expense is reflected in Cost of Sales or Selling, General and Administrative Expenses based on the grantees’ salaries expense classification. We record tax benefits and excess tax benefits related to stock-settled stock appreciation rights (“SSSARs”) and restricted stock awards. These excess tax benefits are included in the operating section of the Consolidated Statements of Cash Flows. We estimate a forfeiture rate for our SSSARs and restricted stock grants based on historical experience. Stock-Settled Stock Appreciation Rights We use periodic grants of SSSARs as a vehicle for rewarding certain employees with long-term incentives for their efforts in helping to create long-term shareholder value. We calculate the fair value of SSSARs grants using the Black-Scholes option-pricing model. Our policy is to issue shares upon SSSARs exercise from new shares that had been previously authorized. In 2020, 2019 and 2018, we granted SSSARs to various employees under the terms of the plans. The following table summarizes information relating to these grants:
| 2020 |  | 2019 |  | 2018
SSSARs granted | 180 |  |  | 157 |  |  | 185 |
Weighted average grant date fair value per right | $ | 24.06 |  |  | $ | 23.55 |  |  | $ | 17.85 |
Weighted average assumptions used in fair value calculations: |  |  |  |  |
Risk-free interest rate | 1.17 | % |  | 2.43 | % |  | 2.39 | %
Dividend yield | 1.81 | % |  | 1.68 | % |  | 1.98 | %
Volatility factor of the expected market price of our common stock | 22.57 | % |  | 21.77 | % |  | 22.57 | %
Expected life in years | 4.01 |  |  | 3.04 |  |  | 2.85 |
For these grants, the volatility factor was estimated based on actual historical volatility of our stock for a time period equal to the term of the SSSARs. The expected average life was determined based on historical exercise experience for this type of grant. The SSSARs we grant generally vest one-third on the first anniversary of the grant date, one-third on the second anniversary of the grant date and one-third on the third anniversary of the grant date. The following table summarizes our SSSARs compensation expense and tax benefits recorded for each of the years ended June 30:
| 2020 |  | 2019 |  | 2018
Compensation expense | $ | 3,049 |  |  | $ | 3,074 |  |  | $ | 2,455 |
Tax benefits | $ | 640 |  |  | $ | 646 |  |  | $ | 690 |
Intrinsic value of exercises | $ | 6,693 |  |  | $ | 6,008 |  |  | $ | 2,381 |
The total fair values of SSSARs vested for each of the years ended June 30 were as follows:
| 2020 |  | 2019 |  | 2018
Fair value of vested rights | $ | 2,972 |  |  | $ | 3,143 |  |  | $ | 2,330 |
The following table summarizes the activity relating to SSSARs granted under the plans for the year ended June 30, 2020:
| Number of Rights |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life in Years |  | Aggregate Intrinsic Value
Outstanding at beginning of year | 586 |  |  | $ | 128.23 |  |  |  |  |
Exercised | (215 | ) |  | $ | 113.89 |  |  |  |  |
Granted | 180 |  |  | $ | 153.73 |  |  |  |  |
Forfeited | (12 | ) |  | $ | 140.29 |  |  |  |  |
Outstanding at end of year | 539 |  |  | $ | 142.16 |  |  | 3.40 |  | $ | 6,976 |
Exercisable and vested at end of year | 208 |  |  | $ | 131.21 |  |  | 2.39 |  | $ | 4,973 |
Vested and expected to vest at end of year | 511 |  |  | $ | 143.23 |  |  | 3.47 |  | $ | 6,072 |
The following table summarizes information about the SSSARs outstanding by grant year at June 30, 2020:
|  | Outstanding |  | Exercisable
|  |  |  |  |  | Weighted Average |  |  |  |
Grant Years |  | Range of Exercise Prices |  | Number Outstanding |  | Remaining Contractual Life in Years |  | Exercise Price |  | Number Exercisable |  | Weighted Average Exercise Price
2020 |  | $153.71-$154.44 |  | 180 |  | 4.64 |  | $153.73 |  | — |  | $—
2019 |  | $148.18-$180.60 |  | 148 |  | 3.67 |  | $154.62 |  | 48 |  | $154.63
2018 |  | $117.76-$124.29 |  | 126 |  | 2.65 |  | $121.12 |  | 75 |  | $121.15
2017 |  | $121.54-$138.96 |  | 66 |  | 1.66 |  | $134.27 |  | 66 |  | $134.27
2016 |  | $101.70 |  | 19 |  | 0.65 |  | $101.70 |  | 19 |  | $101.70
At June 30, 2020, there was $6.1 million of unrecognized compensation expense related to SSSARs that we will recognize over a weighted-average period of 2 years. Restricted Stock We use periodic grants of restricted stock as a vehicle for rewarding our nonemployee directors and certain employees with long-term incentives for their efforts in helping to create long-term shareholder value. In 2020, 2019 and 2018, we granted shares of restricted stock to various employees under the terms of the plans. The following table summarizes information relating to these grants:
| 2020 |  | 2019 |  | 2018
Employees |  |  |  |  |
Restricted stock granted | 31 |  |  | 13 |  |  | 27 |
Grant date fair value | $ | 4,813 |  |  | $ | 2,030 |  |  | $ | 3,218 |
Weighted average grant date fair value per award | $ | 153.72 |  |  | $ | 154.66 |  |  | $ | 121.09 |
The restricted stock under these employee grants vests on the third anniversary of the grant date. Under the terms of our grants, employees receive dividends on unforfeited restricted stock regardless of their vesting status. In 2020, 2019 and 2018, we also granted shares of restricted stock to our nonemployee directors under the terms of the plans. The following table summarizes information relating to each of these grants:
| 2020 |  | 2019 |  | 2018
Nonemployee directors |  |  |  |  |
Restricted stock granted | 5 |  |  | 4 |  |  | 6 |
Grant date fair value | $ | 760 |  |  | $ | 760 |  |  | $ | 759 |
Weighted average grant date fair value per award | $ | 155.70 |  |  | $ | 180.16 |  |  | $ | 123.11 |
The 2020 grant vests over a one-year period, and all of these shares are expected to vest. Dividends earned on the stock during the vesting period will be paid to the directors at the time the stock vests. The following table summarizes our restricted stock compensation expense and tax benefits recorded for each of the years ended June 30:
| 2020 |  | 2019 |  | 2018
Compensation expense | $ | 3,066 |  |  | $ | 2,898 |  |  | $ | 2,584 |
Tax benefits | $ | 644 |  |  | $ | 609 |  |  | $ | 726 |
The total fair values of restricted stock vested for each of the years ended June 30 were as follows:
| 2020 |  | 2019 |  | 2018
Fair value of vested shares | $ | 2,284 |  |  | $ | 3,537 |  |  | $ | 1,508 |
The following table summarizes the activity relating to restricted stock granted under the plans for the year ended June 30, 2020:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Unvested restricted stock at beginning of year | 51 |  |  | $ | 137.17 |
Granted | 36 |  |  | $ | 153.99 |
Vested | (16 | ) |  | $ | 145.28 |
Forfeited | (2 | ) |  | $ | 133.79 |
Unvested restricted stock at end of year | 69 |  |  | $ | 144.27 |
At June 30, 2020, there was $5.5 million of unrecognized compensation expense related to restricted stock that we will recognize over a weighted-average period of 2 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration